Androgen receptor-cofactor interactions as targets for new drug discovery
about
In vitro biologic activities of the antimicrobials triclocarban, its analogs, and triclosan in bioassay screens: receptor-based bioassay screensChemistry and structural biology of androgen receptorA surface on the androgen receptor that allosterically regulates coactivator bindingIdentification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen ReceptorThe potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signallingTriclocarban enhances testosterone action: a new type of endocrine disruptor?Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy.The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens.Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combinationAndrogen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells.Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs)Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling.Development of selective androgen receptor modulators (SARMs).Zimp7 and Zimp10, two novel PIAS-like proteins, function as androgen receptor coregulators.MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cellsThe androgen receptor and its use in biological assays: looking toward effect-based testing and its applications.Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXRDifferential presentation of protein interaction surfaces on the androgen receptor defines the pharmacological actions of bound ligands.Androgen receptor: role and novel therapeutic prospects in prostate cancer.Androgen receptor antagonists: a patent review (2008-2011).Beyond the ligand-binding pocket: targeting alternate sites in nuclear receptors.ELF3 is a repressor of androgen receptor action in prostate cancer cellsA genome-wide RNA interference screen identifies new regulators of androgen receptor function in prostate cancer cellsComparison of in vitro and in vivo screening models for androgenic and estrogenic activities."True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer.Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.Perspectives on designs of antiandrogens for prostate cancer.
P2860
Q23916239-10DC9250-41E2-4133-9751-EDFA6235C88BQ24685498-CE754033-D680-4E6B-B3B3-52075E1A76F4Q27648698-74E94BB7-D5C9-4DCB-8089-50C7ABAD96F5Q27659041-C52AC86A-BF2E-40E5-B1CC-ACFB857D25A2Q28087571-02556D08-D605-46E9-AD98-A48A9131287CQ28259283-041D44E5-27C4-4949-96B0-CE02943B9882Q28280935-77989419-1EC9-420A-AEBF-AF1CB9A69495Q30423500-F0C63CA5-2F60-4D69-A067-3F2BDA146CE4Q33316388-3198CA93-3C9C-4304-A2E5-04183D888D65Q33642558-5DE902A0-C775-4418-A674-821DF4869589Q33706967-B9745A65-967B-437B-961A-59461D2EEF15Q33780204-B15664B1-77D8-412E-A063-4BC90C08FADBQ33856101-6A96C7FA-1681-4894-BFF7-4DF7206B4026Q34558010-4BA84D68-3E94-426E-935E-043E62502A7DQ34803388-4493317B-44B5-4C3D-9F2C-1A2FD4E8054AQ34948292-58EBE241-026F-4A04-9F98-261BD39FEE71Q36509830-DDD41C8A-A136-4E57-A175-9341A6F4D769Q36832670-BBD21BC4-61B8-42A4-947F-8975521FEA0AQ37169881-29930253-EE73-4149-B712-38DE18877ED6Q37256846-4F31D7D8-D44E-40E6-858F-EF71EDCC585BQ38009888-4BBBE605-ABA1-4B8C-BF8D-E73C3A37B5A9Q38076345-619DAF68-4EE9-48CA-98C4-1C9AE94ACF80Q39189616-D754C8F5-3AF2-4590-9948-4A7D32B533D9Q39195814-F51B290C-029A-4698-978D-950E14EE7BE9Q40362575-5B38BAFF-77C8-45A0-AAC0-471C04D204E9Q42026389-88E5947E-0028-475B-9974-1E79A5742650Q42069568-ED0E2398-18A6-4031-B7EE-E524E5D84D32Q46635646-76237022-BC65-4B69-B9E5-CA1F6FB37FF6
P2860
Androgen receptor-cofactor interactions as targets for new drug discovery
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Androgen receptor-cofactor interactions as targets for new drug discovery
@ast
Androgen receptor-cofactor interactions as targets for new drug discovery
@en
Androgen receptor-cofactor interactions as targets for new drug discovery
@nl
type
label
Androgen receptor-cofactor interactions as targets for new drug discovery
@ast
Androgen receptor-cofactor interactions as targets for new drug discovery
@en
Androgen receptor-cofactor interactions as targets for new drug discovery
@nl
prefLabel
Androgen receptor-cofactor interactions as targets for new drug discovery
@ast
Androgen receptor-cofactor interactions as targets for new drug discovery
@en
Androgen receptor-cofactor interactions as targets for new drug discovery
@nl
P3181
P1476
Androgen receptor-cofactor interactions as targets for new drug discovery
@en
P2093
Ching-yi Chang
Donald P McDonnell
P3181
P356
10.1016/J.TIPS.2005.03.002
P407
P577
2005-05-01T00:00:00Z